MétaCan
Menu
Back to cohort
Record W2740721894

The effect of a topical COX-2 inhibitor on the expression of C-Met in a rabbit model of uveal melanoma

2008· article· en· W2740721894 on OpenAlexaff
S. Bakalian, J.–C.A. Marshall, E. Antecka, Sebastian Di Cesare, D. Faingold, Claudia Martins, Bruno F. Fernandes, Miguel N. Burnier

Bibliographic record

VenueCancer Research · 2008
Typearticle
Languageen
FieldEngineering
TopicNanoplatforms for cancer theranostics
Canadian institutionsMcGill University
Fundersnot available
KeywordsMelanomaImmunostainingMedicineMonoclonal antibodyUveaPathologyAntibodyImmunohistochemistryCancer researchImmunology
DOInot available

Abstract

fetched live from OpenAlex

2313 Purpose: Expression of C-Met was significantly associated with melanoma specific mortality in uveal melanoma patients. On the other hand, the expression of cyclooxygenase-2 (COX-2) has been reported as an indicator of poor prognosis in a wide variety of tumors including uveal melanoma. COX-2 inhibitors have shown promise in controlling the malignant characteristics of several types of tumors. Previous work has demonstrated that a COX-2 inhibitor (Nepafenac) has delayed the progression of uveal melanoma as well as the development of metastatic disease in a rabbit model. The aim of this study is to investigate the immunostaining levels of C-Met in the intraocular tumors of non-treated and Nepafenac treated animals. In addition, evaluate the expression levels of C-Met mRNA in non-treated and treated human uveal melanoma cell lines.
 Methods: The animals were divided into two groups of 14 animals each. The control group received drops that contained only the vehicle, while the experimental group received drops containing 0.3% Nepafenac solution. Each group was given two drops, twice daily. The duration of the experiment was 12 week. Twenty-eight cases of paraffin-embedded specimens of uveal melanomas of non-treated and treated rabbits were immuno-stained with C-Met monoclonal antibody using the standard ABC technique. The immunostaining was evaluated in semi-quantitative fashion based on their extent and intensity. The expression levels of C-Met mRNA were assessed in five human uveal melanoma cell lines (92.1, OCM-1, SP6.5, MKT-BR, and UW-1) before and after treatment with Amfenac, the active metabolite of Nepafenac using quantitative Real-time PCR.
 Results: All intraocular tumors showed varying degrees of immunostaining for C-Met. The immunostaining was cytoplasmic in all samples. The intensity of immunostaining was significantly higher in the primary tumors of all non-treated group of rabbits as apposed to the primary tumors of all treated group. All five human uveal melanoma cell lines expressed different amounts of C-Met mRNA. The expression levels of C-Met mRNA were always higher in non-treated cell lines compared to treated cell lines. There was up to four-fold decrease in the expression levels of C-Met mRNA after treatment with Amfenac.
 Conclusion: This is the first study to show that the inhibition of COX-2 causes a down regulation of C-Met in uveal melanoma. Therefore, anti-COX-2 topical medication might be a useful strategy for an adjuvant therapy in uveal melanoma patients. Further studies detailing the pathway of this down regulation are underway.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.048
GPT teacher head0.320
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2008
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicNanoplatforms for cancer theranosticsFrench-language works237,207